Norway’s biotech sector shows its strength in risk-averse times
Biotechnology and risk are synonymous. Now, with the rising price of natural resources and the credit crunch unsettling the financial markets the sector is feeling the pinch as risk-averse investors pull out.

Oslo Cancer Cluster – one year on
Celebrating its first anniversary at BIO, the Oslo Cancer Cluster (OCC) is already well on the road to realizing its vision ‘to transform world class cancer research into new cancer diagnostics and treatment and thereby improve the lives of cancer patients’.
OCC will have a big presence at the BIO Convention in San Diego this month, with a Round Table session with big pharma, and several posters on display.

Potential for major growth in Norwegian Biotech

A recent report from the Boston Consulting Group made for the Norwegian Association of Pharmaceutical Manufacturers, shows a huge potential for growth in the biotech sector in Norway. There is untapped potential related to translating the ideas, technologies, and capabilities coming out of Norwegian biopharma research into more commercial value creation, is the primary conclusion of the report. If Norway manages to play its cards right, the whole sector could increase its total turnover to over 80 billion NOK by 2015. Today the turnover is merely 6 billion NOK.

ALGETA
Algeta is a cancer therapeutics company based in Oslo, Norway. Here CEO Thomas Ramdal runs through the company's exciting prospects for lead product Alpharadin which is based on alpha emitters.

Five company grants from FUGE
FUGE, the Norwegian Research Councils program for functional genomics, recently granted funding to five life science companies: Ewos Innovation AS, siRNAsense AS, Spermatech AS, GenderGuide and PubGen.

Bioprospecting – uncovering Norway’s hidden treasure
The marine environment is a rich, yet largely unexplored, resource which could yield many novel bioactives. While the United States is at the forefront of marine bioprospecting, Norway could also achieve a global position because of its long tradition of harvesting the sea and the rich biodiversity of its Arctic and subArctic water.

Consortium for man-made meat creates mini research council

In a decade you may be able to by hamburgers in the shop, made from a bioreactor and not from a cow. – A novel approach to a problem which will not solve it self, says initiator professor Stig Omholt.

Sonitor’s new patient tag
profiled on US tv

Sonitor’s Real Time Location System (RTLS) ultrasound technology for tracking patients and equipment has already been implemented in 24 US hospitals.

Oslo - The perfect environment to live and work

The fjord, the woods and the culture make Oslo an exiting capital to live in. A blossoming biotech scene adds to the attraction for life scientists.

siRNAsense AS

siRNAsense uses novel techniques within the field of RNA interference to develop new drugs to combat cancer.